Welcome to our dedicated page for Palisade Bio SEC filings (Ticker: PALI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Palisade Bio, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing oral PDE4 inhibitor prodrugs. Disclosures include proxy materials for annual and special stockholder meetings, director elections, auditor ratification, charter-amendment voting matters and compensation-plan governance.
Material-event reports and registration statements cover clinical-development service arrangements, common-stock sales, securities registration, capital-structure updates, Nasdaq listing compliance and meeting adjournment or withdrawal actions. The filings also provide formal context for PALI-2108 development activities, equity financing mechanics, corporate governance and public-company reporting obligations.
Palisade Bio, Inc. reported a larger quarterly loss as it ramps development of its lead IBD drug candidate, but ended the period with substantial cash. For the three months ended March 31, 2026, net loss widened to $9.6 million from $2.2 million a year earlier, driven by higher research and development and general and administrative spending. Research and development expenses rose to $6.4 million, reflecting increased clinical trial and manufacturing activity for PALI-2108 and higher stock-based compensation. General and administrative costs increased to $4.4 million, also largely from stock-based compensation and higher legal fees. The company generated $1.1 million of other income from money market investments following a large equity raise in 2025. Palisade ended the quarter with $132.6 million in cash, cash equivalents and restricted cash and believes this will fund key Phase 2 trials through efficacy readouts in ulcerative colitis and Crohn’s disease. Management still reports a material weakness in internal control over financial reporting and is pursuing remediation.
Palisade Bio, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on director elections, auditor ratification, major share authorization changes, and updated equity plans. The meeting will be held online on June 10, 2026, and only stockholders of record as of April 15, 2026 may vote.
Proposals include electing four directors, ratifying Baker Tilly US, LLP as auditor for 2026, and amending the certificate of incorporation to increase authorized common stock from 300,000,000 to 450,000,000 shares. As of the record date, 167,424,202 common shares were outstanding, with significant additional shares reserved for warrants, options and equity awards.
Stockholders are also asked to approve an amended 2021 Equity Incentive Plan with a fixed pool of 42,257,000 shares and an amended Employee Stock Purchase Plan authorizing 837,000 shares, along with advisory say-on-pay and non‑employee director grant proposals. All proposals require various majority vote standards, and brokers will have discretion only on the auditor and authorized share increase items.
Palisade Bio, Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to elect four directors and seek approval for seven proposals, including an increase in authorized common stock, an amended equity incentive plan, and an amended employee stock purchase plan. As of the Record Date (April 15, 2026), there were 167,424,202 shares outstanding.
The Board asks stockholders to approve amending the Certificate of Incorporation to increase authorized common shares from 300,000,000 to 450,000,000, to approve an Amended and Restated 2021 Equity Incentive Plan reserving 42,257,000 shares, and to approve an Amended and Restated ESPP reserving 837,000 shares. The proxy materials also describe equity overhang from warrants, options and pre-funded warrants and note the company raised approximately $138.0M in an October 2025 financing.
Palisade Bio, Inc. entered into a master services agreement with Iterative Scopes, Inc. d/b/a Iterative Health to help enroll patients in its planned Phase 2 study of PALI-2108 for moderate to severe ulcerative colitis. To support this collaboration, the company issued and sold 1,536,885 shares of common stock to an affiliate of Iterative Health for a total of $3.0 million, at $1.952 per share, which matches the average closing price over the five trading days before the closing date. The shares were sold in a private transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
RA Capital Management and affiliated entities reported a significant passive stake in Palisade Bio, Inc. They beneficially owned 15,746,829 shares of Palisade Bio common stock as of December 31, 2025, representing 9.99% of the outstanding class.
The RA Capital Healthcare Fund directly holds 7,124,116 shares of common stock and pre-funded warrants exercisable for up to 16,614,285 additional shares. A Beneficial Ownership Blocker in the warrants prevents exercises that would push aggregate ownership above 9.99% of the company’s common stock. For Section 13(d) purposes, RA Capital, Peter Kolchinsky, and Rajeev Shah may be deemed beneficial owners but expressly disclaim beneficial ownership outside regulatory reporting.
The ownership percentage is based on 149,003,210 shares outstanding as of November 5, 2025, plus 8,622,713 shares issuable upon warrant exercise. The filing also certifies that the securities are not held to change or influence control of Palisade Bio.
Palisade Bio, Inc. received an updated ownership filing showing that investment entities affiliated with Point72 report a significant passive stake in the company. As of the close of business on December 31, 2025, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen collectively reported beneficial ownership of 10,495,252 shares of Palisade Bio common stock, representing 7.0% of the outstanding class. They report no sole voting or dispositive power, but shared voting and shared dispositive power over all these shares, which are held by Point72 Associates, LLC under an investment management agreement. The filing is made on a Schedule 13G/A basis, with the certifying party stating the securities were not acquired and are not held for the purpose of changing or influencing control of Palisade Bio.
Perceptive Advisors and affiliates reported a significant ownership position in Palisade Bio, Inc. The filing shows beneficial ownership of 15,200,117 shares of common stock, representing 9.99% of the class, including shares underlying pre-funded warrants.
The Master Fund directly holds 12,050,000 common shares and pre-funded warrants for 5,185,714 additional shares at an exercise price of $0.0001 per share, subject to a 9.99% beneficial ownership cap. Ownership percentages are based on 149,003,210 shares outstanding as of November 5, 2025. The reporting persons certify the holdings are not for the purpose of changing or influencing control of Palisade Bio.
Squadron Master Fund LP and related parties report beneficial ownership of 4,500,000 shares of Palisade Bio, Inc. common stock, representing 3.0% of the class. The stake is reported on a Schedule 13G/A as of an event date of 12/31/2025.
The ownership percentage is based on 149,003,210 shares of common stock outstanding as of November 5, 2025, as stated in Palisade Bio’s Form 10-Q filed November 10, 2025. Squadron Capital Management, LLC, as investment adviser to private funds including Squadron Master Fund LP, may be deemed a beneficial owner, and partners Matthew Sesterhenn and William Blank may also be deemed beneficial owners.
All report 0 shares with sole voting or dispositive power and 4,500,000 shares with shared voting and dispositive power. They certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Palisade Bio.